Inventor · disambiguated record
Catherine Anne Eberlein
Also filed as: EBERLEIN CATHERINE ANNE
0 granted patents·5 pending applications·0 citations·filing 2009–2024
Top patents by PatentIndex Score
5 records- 0169US2025108050A1Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancerASTRAZENECA AB·Filed 2024·Application pending·0 cites
- 0258US2012107324A1TARGETED BINDING AGENTS DIRECTED TO a5ß1 AND USES THEREOFEBERLEIN CATHERINE ANNE·Filed 2009·Application pending·0 cites
- 0356US2021177844A1Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancerASTRAZENECA AB·Filed 2020·Application pending·0 cites
- 0450US2012114667A1TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOFEBERLEIN CATHERINE ANNE·Filed 2009·Application pending·0 cites
- 0546US2020237758A1Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancerASTRAZENECA AB·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Catherine Anne Eberlein files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →